 Treatment with the immunosuppressive drug mycophenolate mofetil MMF may result in gastrointestinal GI complications in some patients. This study will assess if a switch from MMF to enteric-coated mycophenolate sodium EC-MPS results in improved GI andor health-related quality of life in liver transplant recipients 